Basel Medical Group Stock
Basel Medical Group Ltd Ordinary Shares
Company data
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Country
- Singapore
- CEO
- Yen Feng Chhoa
- Employees
- 82
- Market cap
- $6 M
- IPO
- 25/02/2025
Basel Medical Group Ltd, an entity established in Singapore in 2023, is dedicated to delivering a comprehensive range of healthcare services. Its operations span multiple key areas, including specialist medical expertise, medical supplies and equipment, advanced medical technology solutions, and pharmaceutical…
Basel Medical Group stock: price history
1D
+1.0%
1W
+5.3%
1M
-3.7%
6M
-42.3%
YTD
-32.8%
1Y
-78.5%
2Y
–
5Y
–
10Y
–
Ask the agents about Basel Medical Group
Basel Medical Group stock metrics
P/E
-14.44
P/B
1.26
EV/EBITDA
-9.86
RETURN ON EQUITY
4.3%
NET MARGIN
3.3%
DEBT/EQUITY
1.57
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
27.8%
FLOAT SHARES
440,578
AVG. DAILY VOLUME (30D)
1,311,488
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Basel Medical Group stock
What does Basel Medical Group do?
Basel Medical Group Ltd Ordinary Shares is a company in the Healthcare sector, Medical - Care Facilities industry, headquartered in Singapore.
The CEO is Yen Feng Chhoa, the company employs around 82 people.
The IPO was on 25/02/2025; the stock trades on NASDAQ under the ticker BMGL.
Does Basel Medical Group pay a dividend?
No, Basel Medical Group currently does not pay a dividend.
Which stocks are comparable to Basel Medical Group?
Comparable stocks include HCA Healthcare, Fresenius, Tenet Healthcare, DaVita, Universal Health Services, Fresenius Medical Care, Hims & Hers Health and LifeStance Health Group.
How can I get Basel Medical Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess Basel Medical Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.